IDENTIFICATION OF GENETIC SIGNATURES AND IMMUNE MECHANISMS THAT DEFINE THERAPEUTIC RESPONSE AND FAILURE TO ANTI-INTEGRIN THERAPY WITH VEDOLIZUMAB IN IBD PATIENTS

(1) Friedrich-Alexander University Erlangen-Nuremberg,Department of Medicine I, Division of Gastroenterology,Erlangen,Germany

(2) Friedrich-Alexander University Erlangen-Nuremberg,Department of Human Genetics,Erlangen,Germany

(3) Klinikum Bayreuth,Abt. Pathologie,Bayreuth,Germany



This item was part of UEG Week 2017

This item can be cited as: United European Gastroenterology Journal 2017; 5 (Supplement 1)